Stock STOK STOKE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
11.48 USD -4.41% Intraday chart for Stoke Therapeutics, Inc. -4.49% +118.25%
05-07 Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating MT
05-06 Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Stoke Therapeutics : Corporate Presentation - May 2024
PU
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BU
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
BU
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BU
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BU
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BU
Stoke Therapeutics Announces Proposed Public Offering
BU
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
BU
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
BU
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Stoke Therapeutics Presents Data from Multiple Studies of Children and Adolescents with Dravet Syndrome at the American Epilepsy Society 2023 Annual Meeting
AQ
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
BU
Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
AQ
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
BU
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
BU
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STOK Stock
  4. News Stoke Therapeutics, Inc.
  5. Press Releases